Summary

Persistence Market Research has recently released a comprehensive report on the global Biomarker Discovery Outsourcing Services Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Biomarker Discovery Outsourcing Services Market Size (2025E): US$ 14.8 Bn
• Projected Market Value (2032F): US$ 38.4 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 14.5%

Biomarker Discovery Outsourcing Services Market - Report Scope:

The biomarker discovery outsourcing services market includes a range of services provided to pharmaceutical and biotechnology companies to identify and validate biomarkers that can serve as indicators of disease state, therapeutic response, or drug toxicity. These services encompass advanced technologies such as genomics, proteomics, and bioinformatics. Outsourcing these activities enables life sciences organizations to accelerate drug development, reduce costs, and gain access to specialized expertise and infrastructure. With the increasing focus on precision medicine, early disease detection, and targeted therapy, the demand for biomarker discovery outsourcing is experiencing robust growth.

Market Growth Drivers:

Several key factors are propelling the growth of the global biomarker discovery outsourcing services market. The rising demand for personalized medicine is one of the most significant drivers, as biomarkers play a critical role in tailoring treatments to individual patient profiles. The increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions is pushing pharmaceutical companies to identify novel biomarkers for early diagnosis and monitoring. Technological advancements in high-throughput screening, genomics, and artificial intelligence are further enhancing biomarker discovery capabilities. Moreover, outsourcing offers cost advantages, access to global talent, and faster turnaround times, making it an attractive option for both large pharmaceutical firms and smaller biotechnology companies.

Market Restraints:

Despite strong growth prospects, the market faces a few constraints. One of the primary challenges is the complexity and high cost of biomarker validation, which can extend the development timeline. Regulatory uncertainties and stringent approval pathways for biomarker-based diagnostics and therapeutics can also hinder market expansion. Additionally, concerns around data security, especially when outsourcing across borders, and the lack of standardized procedures for biomarker validation may limit wider adoption of outsourcing services.

Market Opportunities:

The market presents significant growth opportunities driven by the expanding pipeline of biologics and the surge in clinical trials focused on precision therapies. Emerging economies, particularly in Asia-Pacific and Latin America, offer untapped potential for outsourcing due to their cost-efficiency and improving research infrastructure. Collaborations between contract research organizations (CROs) and pharmaceutical companies are becoming more strategic, focusing on long-term partnerships rather than transactional models. Furthermore, advances in multi-omics approaches, machine learning, and digital biomarker discovery are opening new avenues for innovation and efficiency in outsourced services.

Key Questions Answered in the Report:

• What are the primary factors driving the global biomarker discovery outsourcing services market's growth?
• Which regions and biomarker types are showing the most potential for expansion?
• How are technological innovations shaping the future of biomarker discovery outsourcing?
• Who are the major players, and what strategies are they deploying to stay competitive?
• What are the key regulatory and operational challenges in the market?

Competitive Intelligence and Business Strategy:

Leading players in the global biomarker discovery outsourcing services market, such as Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Charles River Laboratories, Eurofins Scientific, and ICON plc, are focusing on expanding their service portfolios through strategic acquisitions, technology integration, and global partnerships. These companies are investing in high-throughput and multi-omics technologies, AI-based data analytics, and integrated platforms to deliver comprehensive biomarker solutions. Strengthening collaborations with biopharma companies and enhancing R&D capabilities are also key strategies for sustaining long-term growth and competitiveness in this dynamic market.

Companies Covered in This Report:

• Laboratory Corporation of America Holdings
• Celerion
• Charles River Laboratories
• Eurofins Scientific
• GHO Capital
• ICON plc
• Evotec
• Parexel International (MA) Corporation
• Thermo Fisher Scientific Inc.
• Proteome Sciences

Market Segmentation:

By Biomarker Type:

• Predictive Biomarkers
• Prognostic Biomarkers
• Safety Biomarkers
• Surrogate Biomarkers

By Therapeutic Area:

• Oncology
• Cardiology
• Neurology
• Autoimmune Diseases
• Others

By Discovery Phase:

• Biomarker Identification
• Biomarker Validation
• Biomarker Profiling
• Biomarker Panel Development
• Biomarker Selection

By End-use:

• Pharmaceutical Companies
• Biotechnology Companies
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Biomarker Discovery Outsourcing Services Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Key Trends
2.3. Macro-economic Factors
2.3.1. Impact of International Trade Policies on Analytical Instruments
2.3.2. Economic Recovery and Increased Research Spending in Healthcare
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Biomarker Type Demand Analysis
3.2. Regulatory Landscape
3.3. Value Chain Analysis
3.4. PESTLE Analysis
3.5. Porter’s Five Force Analysis
4. Global Biomarker Discovery Outsourcing Services Market Outlook
4.1. Key Highlights
4.1.1. Market Volume (Units) Projections
4.1.2. Market Size (US$ Bn) and Y-o-Y Growth
4.1.3. Absolute $ Opportunity
4.2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
4.3. Global Biomarker Discovery Outsourcing Services Market Outlook: Biomarker Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Biomarker Type, 2019-2024
4.3.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
4.3.3.1. Predictive Biomarkers
4.3.3.2. Prognostic Biomarkers
4.3.3.3. Safety Biomarkers
4.3.3.4. Surrogate Biomarkers
4.3.4. Market Attractiveness Analysis: Biomarker Type
4.4. Global Biomarker Discovery Outsourcing Services Market Outlook: Therapeutic Area
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Therapeutic Area, 2019-2024
4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
4.4.3.1. Oncology
4.4.3.2. Cardiology
4.4.3.3. Neurology
4.4.3.4. Autoimmune Diseases
4.4.3.5. Others
4.4.4. Market Attractiveness Analysis: Therapeutic Area
4.5. Global Biomarker Discovery Outsourcing Services Market Outlook: Discovery Phase
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Discovery Phase, 2019-2024
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
4.5.3.1. Biomarker Identification
4.5.3.2. Biomarker Validation
4.5.3.3. Biomarker Profiling
4.5.3.4. Biomarker Panel Development
4.5.3.5. Biomarker Selection
4.5.4. Market Attractiveness Analysis: Discovery Phase
4.6. Global Biomarker Discovery Outsourcing Services Market Outlook: End Use
4.6.1. Introduction / Key Findings
4.6.2. Historical Market Size (US$ Bn) Analysis, By End Use, 2019-2024
4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
4.6.3.1. Pharmaceutical Companies
4.6.3.2. Biotechnology Companies
4.6.3.3. Others
4.6.4. Market Attractiveness Analysis: End Use
5. Global Biomarker Discovery Outsourcing Services Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019-2024
5.3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Biomarker Discovery Outsourcing Services Market Outlook
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
6.2.1. By Country
6.2.2. By Biomarker Type
6.2.3. By Therapeutic Area
6.2.4. By Discovery Phase
6.2.5. By End Use
6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
6.4.1.
6.4.1.1.
6.4.1.1.1. Predictive Biomarkers
6.4.1.1.2. Prognostic Biomarkers
6.4.1.1.3. Safety Biomarkers
6.4.1.1.4. Surrogate Biomarkers
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
6.5.1. Oncology
6.5.2. Cardiology
6.5.3. Neurology
6.5.4. Autoimmune Diseases
6.5.5. Others
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
6.6.1. Biomarker Identification
6.6.2. Biomarker Validation
6.6.3. Biomarker Profiling
6.6.4. Biomarker Panel Development
6.6.5. Biomarker Selection
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
6.7.1. Pharmaceutical Companies
6.7.2. Biotechnology Companies
6.7.3. Others
6.8. Market Attractiveness Analysis
7. Europe Biomarker Discovery Outsourcing Services Market Outlook
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Biomarker Type
7.2.3. By Therapeutic Area
7.2.4. By Discovery Phase
7.2.5. By End Use
7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
7.4.1.
7.4.1.1.
7.4.1.1.1. Predictive Biomarkers
7.4.1.1.2. Prognostic Biomarkers
7.4.1.1.3. Safety Biomarkers
7.4.1.1.4. Surrogate Biomarkers
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
7.5.1. Oncology
7.5.2. Cardiology
7.5.3. Neurology
7.5.4. Autoimmune Diseases
7.5.5. Others
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
7.6.1. Biomarker Identification
7.6.2. Biomarker Validation
7.6.3. Biomarker Profiling
7.6.4. Biomarker Panel Development
7.6.5. Biomarker Selection
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
7.7.1. Pharmaceutical Companies
7.7.2. Biotechnology Companies
7.7.3. Others
7.8. Market Attractiveness Analysis
8. East Asia Biomarker Discovery Outsourcing Services Market Outlook
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Biomarker Type
8.2.3. By Therapeutic Area
8.2.4. By Discovery Phase
8.2.5. By End Use
8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
8.4.1.
8.4.1.1.
8.4.1.1.1. Predictive Biomarkers
8.4.1.1.2. Prognostic Biomarkers
8.4.1.1.3. Safety Biomarkers
8.4.1.1.4. Surrogate Biomarkers
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
8.5.1. Oncology
8.5.2. Cardiology
8.5.3. Neurology
8.5.4. Autoimmune Diseases
8.5.5. Others
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
8.6.1. Biomarker Identification
8.6.2. Biomarker Validation
8.6.3. Biomarker Profiling
8.6.4. Biomarker Panel Development
8.6.5. Biomarker Selection
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
8.7.1. Pharmaceutical Companies
8.7.2. Biotechnology Companies
8.7.3. Others
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Biomarker Discovery Outsourcing Services Market Outlook
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Biomarker Type
9.2.3. By Therapeutic Area
9.2.4. By Discovery Phase
9.2.5. By End Use
9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
9.4.1.
9.4.1.1.
9.4.1.1.1. Predictive Biomarkers
9.4.1.1.2. Prognostic Biomarkers
9.4.1.1.3. Safety Biomarkers
9.4.1.1.4. Surrogate Biomarkers
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
9.5.1. Oncology
9.5.2. Cardiology
9.5.3. Neurology
9.5.4. Autoimmune Diseases
9.5.5. Others
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
9.6.1. Biomarker Identification
9.6.2. Biomarker Validation
9.6.3. Biomarker Profiling
9.6.4. Biomarker Panel Development
9.6.5. Biomarker Selection
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
9.7.1. Pharmaceutical Companies
9.7.2. Biotechnology Companies
9.7.3. Others
9.8. Market Attractiveness Analysis
10. Latin America Biomarker Discovery Outsourcing Services Market Outlook
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Biomarker Type
10.2.3. By Therapeutic Area
10.2.4. By Discovery Phase
10.2.5. By End Use
10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
10.4.1.
10.4.1.1.
10.4.1.1.1. Predictive Biomarkers
10.4.1.1.2. Prognostic Biomarkers
10.4.1.1.3. Safety Biomarkers
10.4.1.1.4. Surrogate Biomarkers
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
10.5.1. Oncology
10.5.2. Cardiology
10.5.3. Neurology
10.5.4. Autoimmune Diseases
10.5.5. Others
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
10.6.1. Biomarker Identification
10.6.2. Biomarker Validation
10.6.3. Biomarker Profiling
10.6.4. Biomarker Panel Development
10.6.5. Biomarker Selection
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
10.7.1. Pharmaceutical Companies
10.7.2. Biotechnology Companies
10.7.3. Others
10.8. Market Attractiveness Analysis
11. Middle East & Africa Biomarker Discovery Outsourcing Services Market Outlook
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Biomarker Type
11.2.3. By Therapeutic Area
11.2.4. By Discovery Phase
11.2.5. By End Use
11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Biomarker Type, 2025-2032
11.4.1.
11.4.1.1.
11.4.1.1.1. Predictive Biomarkers
11.4.1.1.2. Prognostic Biomarkers
11.4.1.1.3. Safety Biomarkers
11.4.1.1.4. Surrogate Biomarkers
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Therapeutic Area, 2025-2032
11.5.1. Oncology
11.5.2. Cardiology
11.5.3. Neurology
11.5.4. Autoimmune Diseases
11.5.5. Others
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Discovery Phase, 2025-2032
11.6.1. Biomarker Identification
11.6.2. Biomarker Validation
11.6.3. Biomarker Profiling
11.6.4. Biomarker Panel Development
11.6.5. Biomarker Selection
11.7. Current Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025-2032
11.7.1. Pharmaceutical Companies
11.7.2. Biotechnology Companies
11.7.3. Others
11.8. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Laboratory Corporation of America Holdings
12.3.1.1. Overview
12.3.1.2. Segments and Biomarker Types
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Celerion
12.3.3. Charles River Laboratories
12.3.4. Eurofins Scientific
12.3.5. GHO Capital
12.3.6. ICON plc
12.3.7. Evotec
12.3.8. Parexel International (MA) Corporation
12.3.9. Thermo Fisher Scientific Inc.
12.3.10. Proteome Sciences
12.3.11. Others
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations